Company Filing History:
1 out of 525 
1 out of 185 
2 out of 832,891 Years Active: 2001-2007
Title: Jurgen Kurthals: Innovator in Cancer Research
Introduction
Jurgen Kurthals is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research, particularly through his work on tumor-associated peptides. With a total of 3 patents, his innovations have the potential to impact the diagnosis and treatment of cancer.
Latest Patents
One of his latest patents involves MAGE-3 peptides presented by HLA class II molecules. This invention describes HLA class II binding peptides encoded by the MAGE-3 tumor-associated gene. It also includes nucleic acids encoding such peptides and antibodies related to them. The peptides are designed to stimulate the activity and proliferation of CD4 T lymphocytes. Additionally, methods and products are provided for diagnosing and treating conditions characterized by the expression of the MAGE-3 gene.
Career Highlights
Throughout his career, Jurgen has worked with prestigious organizations, including the Ludwig Institute for Cancer Research Limited. His work has focused on advancing the understanding of cancer biology and developing innovative therapeutic strategies.
Collaborations
Jurgen has collaborated with notable colleagues such as Pascal Chaux and Vincent Stroobant. These partnerships have contributed to the advancement of research in the field of cancer.
Conclusion
Jurgen Kurthals is a prominent figure in cancer research, with a focus on innovative solutions for diagnosis and treatment. His contributions through patents and collaborations highlight his commitment to advancing medical science.